Alivus Life Sciences Ltd
Alivus Life Sciences Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
FY’26 volume growth expected in mid-teens, driven by new product launches and opening of new markets. Volume Growth:** Mid-teens volume growth expected in FY’26 driven by new product launches and market expansion.
From Alivus Life Sciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY’26 volume growth expected in mid-teens, driven by new product launches and opening of new markets.
- Revenue growth projected to be in high single digits due to pricing erosion despite volume growth.
- Incremental volume growth primarily from newer product sites, though base products continue solid volume growth.
- CDMO business expected to grow significantly with 4th project reaching full potential by end FY’25 and 5th project obtaining regulatory approval in second half FY’26.
- Longer-term, growth is backed by a strong pipeline with product launches aligned with patent expiries starting FY’28.
- Company remains optimistic about future trajectory supported by favorable demand environment and healthy order book.
- Margins expected to stabilize in the 28% to 30% range going forward.
Profitability & Margins
See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total planned CAPEX for FY’26 is upwards of Rs. 550 crores (Rs. 550-600 crores range).
- Major CAPEX includes:
- - Greenfield expansion in Solapur.
- - Brownfield expansions in Ankleshwar and Dahej to be completed this year.
- - New R&D center near Mumbai with Rs. 70-80 crores allocated.
- The 2650 KL volume expansion initially planned for FY’27 is now pushed to FY’28 due to brownfield expansions providing sufficient capacity for next 2-3 years.
- Asset turnover may be lower initially during this investment phase but expected to reach around 2x gradually.
- Focus remains on completing brownfield expansions and Solapur Phase 1 (300 KL) by Q4 FY’26.
- No new debt planned for FY’26-27; company remains net debt-free.
- Strategic collaborations and platform developments are ongoing with updates expected in second half or end of FY’26.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The CDMO business has a small base with three commercial projects currently driving volume.
- The 4th CDMO project started commercializing in Q3 of the previous year but is on a slow uptake, expected to reach full potential by end of the current year.
- The 5th CDMO project is under regulatory approvals, with an anticipated approval for use as an API source in the second half of FY’26.
- There are ongoing discussions and multiple projects ("irons in the fire") in the CDMO pipeline aimed at bringing more projects by late FY’26 or early FY’27.
- Average size of CDMO contracts is around Rs.50 to Rs.60 crore, targeting lifecycle management and 505 B2 therapies.
- The company expects a back-loaded CDMO order book performance for the current year, with growth kicking in more towards the latter half.
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹689 Cr, net profit ₹163 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules Ltd (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q4 FY25 results?
FY’26 volume growth expected in mid-teens, driven by new product launches and opening of new markets. Volume Growth:** Mid-teens volume growth expected in FY’26 driven by new product launches and market expansion.
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
Total planned CAPEX for FY’26 is upwards of Rs.
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.